Cargando…
AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19
The impact of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19, is global and unprecedented. Although remdesivir has recently been approved by the FDA to treat SARS-CoV-2 infection, no oral antiviral is available for outpatient treatment. AT-527, an orall...
Autores principales: | Good, Steven S., Westover, Jonna, Jung, Kie Hoon, Zhou, Xiao-Jian, Moussa, Adel, La Colla, Paolo, Collu, Gabriella, Canard, Bruno, Sommadossi, Jean-Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097421/ https://www.ncbi.nlm.nih.gov/pubmed/33558299 http://dx.doi.org/10.1128/AAC.02479-20 |
Ejemplares similares
-
Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with In Vitro and In Vivo Activity against Dengue and Other Flaviviruses
por: Good, Steven S., et al.
Publicado: (2021) -
Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis
por: Berliba, Elina, et al.
Publicado: (2019) -
Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus
por: Good, Steven S., et al.
Publicado: (2020) -
AT-752, a double prodrug of a guanosine nucleotide analog, inhibits yellow fever virus in a hamster model
por: Lin, Kai, et al.
Publicado: (2022) -
Nucleotide Prodrug Containing a Nonproteinogenic Amino Acid To Improve Oral Delivery of a Hepatitis C Virus Treatment
por: Feng, Joy Y., et al.
Publicado: (2018)